Through a series of studies, Zhang et al. showed that selenomethionine enhanced the antioxidant capacity, mitigated Aβ and tau pathology, reversed synaptic deficits, and ameliorated cognitive decline in AD mice (Song et al., 2014; Zhang et al., 2016, 2017a, 2018), demonstrating the multitarget effect of Se in AD treatment. The gene discussed is MAPT; the disease is Alzheimer disease.